RIN Institute

RIN Institute

Rin Research Institute is a venture company that develops unique antibody drugs that are useful in cancer diagnosis and treatment. Learn more

Launch date
Employees
Market cap
-
Enterprise valuation
€1—2m (Dealroom.co estimates Apr 2020.)
Tokyo Japan (HQ)
  • Edit
DateInvestorsAmountRound

N/A

Spinout
N/A

JPY28.0m

Seed
N/A

JPY99.0m

Series A
N/A

JPY3.0m

Early VC

JPY201m

Late VC
N/A

JPY50.0m

Series B

JPY200m

Late VC

N/A

-

$3.6m

Late VC
Total Funding€7.4m

Recent News about RIN Institute

Edit
More about RIN Instituteinfo icon
Edit

Rinmab Co., Ltd. specializes in providing advanced research and development (R&D) solutions tailored for medical and exclusive associations. Operating within the niche market of medical research, the company focuses on enhancing the capabilities of its clients through cutting-edge technology and expert advisory services. Rinmab serves a diverse clientele, including national research institutes and specialized medical associations, aiming to drive innovation and development in the medical field. The business model revolves around offering bespoke R&D services, consultancy, and technological solutions that cater to the unique needs of its clients. Revenue is generated through service contracts, consultancy fees, and long-term partnerships with research institutions. Rinmab's commitment to advancing medical research positions it as a key player in the industry, fostering growth and innovation.

Keywords: R&D solutions, medical research, exclusive associations, consultancy, technology, innovation, development, niche market, advisory services, partnerships.